Nephrocare Health IPO: Analysis and Allotment Status
The Nephrocare Health Services IPO, a company providing complete dialysis care, is nearing its allotment stage. The initial public offering (IPO) saw good interest from investors. The final details regarding share allocation are expected to be announced shortly, impacting investment decisions.
Key Points
- IPO subscription was 14.08 times, showing strong investor interest.
- QIBs booked shares 26.82 times, highlighting institutional demand.
- NIIs subscribed 24.77 times, indicating broad participation.
- Retail investors subscribed only 2.36 times, a lower uptake.
- Shares will list on BSE and NSE on December 17, 2025.
- Allotment details expected today, December 15, 2025.
Investor response to the Nephrocare Health IPO was significant, with subscriptions exceeding the initial offering by a substantial margin. This indicates a positive outlook for the company and its services. The final allotment process will determine the distribution of shares among investors.
The grey market trading of Nephrocare Health’s unlisted shares suggests investor anticipation. Shares were trading at ₹494.5 per share, a 7.5% premium compared to the IPO’s price range. This premium reflects the market’s confidence in the company’s potential.
The IPO subscription period ran from Wednesday, December 10th to Friday, December 12th, 2025. Following allocation, the company plans to initiate refunds and share transfers on December 16th, 2025. Shares will then officially list on both the BSE and NSE on December 17th, 2025.
“Ultimately, successful IPO allotments signal a confident outlook for Nephrocare Health’s long-term growth.”
